
Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit is an episode from FierceBiotech Radio. Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accus...
This episode belongs to FierceBiotech Radio.
Use the player on this page to stream the episode online.
Published Nov 12, 2015, 32:02 long, audio available.
Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.
You can listen to Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit online on Radio and Podcast. Open the player on this page to stream the available audio.
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit is an episode from FierceBiotech Radio.
This episode is 32:02 long.
This episode was published on Nov 12, 2015.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from FierceBiotech Radio when more episodes are available from the podcast feed.
You can listen to Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit on this page when the episode audio is available from the podcast feed.
Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit is from FierceBiotech Radio.
Published Nov 12, 2015 and 32:02 long